Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
KPV, derived from -MSH, inhibits NF-B activation and reduces pro-inflammatory cytokines in models of colitis and skin inflammation, offering enhanced gut and systemic anti-inflammatory benefits over GLOWs formulation
JAMA Network Open 8 , e2457349e2457349 (2025)
Phase 2 Trial Results: Weight Loss Outcomes in Type 2 Diabetes At the highest 12 mg dose, adults with type 2 diabetes achieved approximately 16.9% mean body weight reduction from baseline at 24 weeks in a randomised, placebo-controlled phase 2 trial published in The Lancet (2023)
This early window is when your GLP-1 receptors begin responding to the medication, signaling fullness to your brain and slowing gastric emptying
US$ 29.50
US$ 24.86
US$ 28.00
US$ 25.09
